Skip to main content
Full access
Open Forum
Published Online: 15 April 2021

Lessons From Maslow: Prioritizing Funding to Improve the Quality of Community Mental Health and Substance Use Services

Abstract

Evidence-based practices (EBPs) are frequently proposed as an approach to close the quality chasm in behavioral health treatment, and many U.S. municipalities are investing in EBPs as a primary way to improve the quality of care delivered to individuals most in need. In this Open Forum, the authors argue that EBPs often cannot be successfully implemented because basic organizational needs are not met in the current fiscal environment. The authors summarize research that supports why EBPs, along with other approaches to improve quality, are likely to fail until there is adequate financing. They also propose a policy and research agenda to ameliorate and address the fiscal challenges inherent in community mental health and substance use services.
Increasing the quality of health care in community settings is a primary focus of public health policy. Recently, federal and regional organizations have invested heavily in the implementation of evidence-based practice (EBP) to reduce the variability in service quality and outcomes in health care. The face validity of this approach is appealing. Ultimately, however, these efforts may fail for the same complex reasons that drive the variability in service quality and outcomes in the first place. We argue for prioritizing policy reform and increased funding to improve the quality of community mental health and substance use services.
This perspective stems from decades of work in partnership with Philadelphia’s public mental health and substance use system. We have collaborated with system leadership to advise on and study EBP implementation with a suite of approaches, including observations, interviews, and surveys. Studying the rollout of system-wide policies and initiatives designed to increase EBP use has enabled us to uncover the stressed financial infrastructure of mental health and substance use services (1, 2). Despite inspired leadership and dedicated policy makers, payers, agency leaders, and clinicians, we have not overcome the systemic challenges in the business of delivering mental health and substance use treatment. Community agencies are in dire financial straits (3), causing many administrators to make the difficult decision to shift their workforce from salaried clinicians to independent contractors (4). We know little about the consequences of this change, although organizational research from other work settings suggests that it will likely not result in better care. Agency leader and clinician turnovers happen frequently, which affects agency culture, patient engagement, and outcomes.
Agency leaders unanimously tell us, “EBPs are great, but I have to keep the lights on,” prompting us to consider Maslow’s hierarchy of needs as it applies to public mental health and substance use services. Maslow posited that basic needs, such as food and water, must be met before one can achieve higher-level needs. In a similar vein, the agencies serving our most vulnerable citizens are struggling to stay solvent. Implementing EBP is akin to a higher-level need—agency leaders endorse it as a priority, but in the same breath, ask how they can achieve this goal given their uncertain financial landscape and other organizational pressures. We are staunch believers in the value of EBPs; however, we have concluded that EBPs will not solve these financial problems, nor will any of the other many initiatives to improve the quality of care, such as performance contracting, measurement-based care, learning mental health systems, or value-based purchasing. These approaches often layer complex requirements onto already stressed environments. Initiatives to improve service quality shift with the times and with funder priorities, but the importance of adequate funding holds steady. The need to address these fundamental barriers to high-quality, evidence-based mental health and substance use services and the importance of adequate funding is not idiosyncratic to Philadelphia, where we conduct our research. Adequate funding is a key factor in most leading implementation science frameworks (5). National evaluations of EBP implementation and sustainability all have found that inadequate funding, particularly low reimbursement rates, is the single most critical factor in an organization’s decision to adopt, sustain, or discontinue an EBP (6).
At the time of this writing, the COVID-19 pandemic has been raging in the United States over the past 7 months. The suffering, tragic losses, and economic hardships are likely only beginning. The full impacts of the pandemic on individuals who have, or are vulnerable to, mental health and substance use problems are still unknown, but many of these individuals will almost certainly experience ramifications arising from the general medical and psychological impacts of this disease (7). A focus on funding for our community mental health and substance use treatment systems will be crucial in the aftershocks of COVID-19. Our hope is that the new acknowledgment of the importance of mental health in the United States in light of the COVID-19 pandemic may present an opportunity for reforming mental health and substance use policies and for delivering a large infusion of resources. Below we describe three policy directions and provide research recommendations for improving quality of care in community mental health and substance use, beginning with increased funding.

Increase Funding

Policy reform is needed to increase funding for mental health treatment and substance use prevention and intervention. Increasing reimbursement rates is the first and most critical step because payment for intervention is lower than for every other area in medicine. One in two Americans will have a mental health or substance use condition in their lifetime. The opioid crisis, considered the greatest preventable public health crisis of the current generation, is caused by a treatable substance use disorder. Directly related to deteriorating national mental health in the United States, suicide rates are increasing in all age groups, particularly among school-age youths and adolescents (8). Yet, federal funding for mental health and substance use treatment comprises only 7% of total U.S. health care spending. Funding for substance use treatment is actually shrinking (5).
We need to advocate more effectively for prioritizing and valuing mental health and substance use treatment in this country. As a result of chronic underfunding, a less trained workforce delivers mental health and substance use care (911). Increasing rates will buoy an underpaid workforce and attract and retain trained clinicians. Enhanced reimbursement will pay agencies operating on the slimmest of margins and support systematic change so that agencies have the bandwidth and capacity to devote efforts to high-quality care rather than worrying about how to keep the lights on. The opioid epidemic, and even more recently the response to COVID-19, have revealed that swift and major changes in funding and regulation can happen in a matter of weeks. For example, Congress appropriated billions of dollars to expand treatment for opioid use disorder, and insurers have dramatically changed regulations regarding telemedicine to expand treatment during the pandemic. We should take similar approaches to increasing reimbursement rates to attract, develop, and support a highly qualified workforce and the organizations who serve individuals with mental health and substance use difficulties.

Clarify Incentives and Outcomes

An increase in funding is necessary but not sufficient. Skeptics may argue that multiple large-scale demonstrations have so far not been effective. Evidence for the effectiveness of pay-for-performance and alternative payment arrangements in behavioral health is modest at best (12, 13). We believe these large-scale demonstration projects have not worked for at least three reasons. First, it is possible that the incentives have not been large enough to overcome the preexisting severe fiscal constraints in these organizations (14). Second, incentives are often designed by payers and do not follow the evidence base for providing effective rewards, such as being salient and timely. Incentives are typically not developed in collaboration with multiple stakeholders, including agency leaders and clinicians. Our previous research shows that payers use incentives that are easy to deploy (such as paying for training) rather than those they perceive as most effective (such as paying for outcomes) (15), suggesting misalignment. More research is needed on incentive effectiveness, whom to incent (e.g., clinician or agency), how to make incentives more salient and impactful in these environments, and how to remove barriers to deploying complex incentives.
Third, and perhaps most importantly, as a field we still have not reached consensus on outcomes in mental health and substance use (16). Without agreed-upon outcome measures, we lack incentives. There are still few endorsed measures of key behavioral processes and outcomes, especially recovery outcomes. This reinforces a misconception that treatment for behavioral health conditions cannot be precisely measured. This further puts payers in a difficult dilemma of figuring out what to pay for. Our failure as a field to identify and establish outcomes has harmed the people for whom the incentives are most intended to help.

Partnership With Accountability

Measuring and incentivizing outcomes both engender accountability. To do this effectively, research and business partnerships with behavioral health treatment organizations should be established. Community agencies have many competing demands, from providing care to patients with complex conditions to remaining solvent under shrinking budgets. Many agencies may benefit from partnerships with researchers who can help them shoulder the immense task of measurement-based care. We must draw from the organizational literature and established business models to ensure that publicly funded agencies are operating at maximum efficiency. With established measures, researchers need to partner with community agencies to demonstrate to payers and policy makers that increased funding is the right thing to do not just from a societal perspective, but also from a business, decision-maker, and payer perspective. We must also accrue evidence on how to make the delivery of high-quality care more cost-effective to optimize the return on investment from behavioral health dollars. For example, do enhanced rates, increased consumer demand, or reduced no-show rates make EBPs profitable for an agency to implement? Last, we must further prioritize research on how to finance and align data collection and infrastructure at the organizational level so that it supports high-quality care and creates data environments conducive to high-quality care.
EBPs will never be the sole panacea for the quality chasm in the current fiscal mental health and substance use treatment environments. The lessons of Maslow and the reality of the financial challenges facing our system suggest that our field needs a paradigm shift toward prioritizing increased funding. Only by increasing funding can we create structures and processes to enhance and optimize the use of behavioral health dollars to improve the quality of care through EBPs or other initiatives. Without such shift, our efforts to improve will remain in vain.

Acknowledgments

The authors are grateful for the mentorship and friendship of Trevor Hadley (1946–2020), a man who devoted his career to improving care for people with mental illness. The authors also thank their community partners, especially the Department of Behavioral Health and Intellectual DisAbility Services and Community Behavioral Health in Philadelphia.

Footnotes

This study was supported by the Institute of Mental Health (awards K23 MH-099179, F32 MH-103960, and P50 MH-113840) and National Institute on Drug Abuse (award K23 DA048167).
Dr. Beidas reports receiving royalties from Oxford University Press, providing consultation to the Camden Coalition of Healthcare Providers, and serving as a member of the Optum Behavioral Health Clinical Scientific Advisory Council. The other authors report no financial relationships with commercial interests.

References

1.
Beidas RS, Marcus S, Aarons GA, et al: Predictors of community therapists’ use of therapy techniques in a large public mental health system. JAMA Pediatr 2015; 169:374–382.
2.
Beidas RS, Stewart RE, Adams DR, et al: A multi-level examination of stakeholder perspectives of implementation of evidence-based practices in a large urban publicly-funded mental health system. Adm Policy Ment Health 2016; 43:893–908.
3.
Stewart RE, Adams DR, Mandell DS, et al: The perfect storm: collision of the business of mental health and the implementation of evidence-based practices. Psychiatr Serv 2016; 67:159–161.
4.
Beidas RS, Stewart RE, Benjamin Wolk C, et al: Independent Contractors in Public Mental Health Clinics: Implications for Use of Evidence-Based Practices. Psychiatr Serv 2016; 67:710–717.
5.
Raghavan R, Bright CL, Shadoin AL: Toward a policy ecology of implementation of evidence-based practices in public mental health settings. Implement Sci 2008; 3:26.
6.
Bond GR, Drake RE, McHugo GJ, et al: Long-term sustainability of evidence-based practices in community mental health agencies. Adm Policy Ment Health 2014; 41:228–236.
7.
Torales J, O’Higgins M, Castaldelli-Maia JM, et al: The outbreak of COVID-19 coronavirus and its impact on global mental health. Int J Soc Psychiatry 2020; 66:317–320.
8.
Miron O, Yu K-H, Wilf-Miron R, et al: Suicide rates among adolescents and young adults in the United States, 2000–2017. JAMA 2019; 321:2362–2364.
9.
Scheffler RM, Kirby PB: The occupational transformation of the mental health system. Health Aff 2003; 22:177–188.
10.
Weil TP: Insufficient dollars and qualified personnel to meet United States mental health needs. J Nerv Ment Dis 2015; 203:233–240.
11.
Baker TB, McFall RM, Shoham V: Current status and future prospects of clinical psychology: toward a scientifically principled approach to mental and behavioral health care. Psychol Sci Public Interest 2008; 9:67–103.
12.
Stewart RE, Lareef I, Hadley TR, et al: Can we pay for performance in behavioral health care? Psychiatr Serv 2017; 68:109–111.
13.
Carlo AD, Benson NM, Chu F, et al: Association of alternative payment and delivery models with outcomes for mental health and substance use disorders: a systematic review. JAMA Netw Open 2020; 3:e207401.
14.
Stewart MT, Reif S, Dana B, et al: Incentives in a public addiction treatment system: effects on waiting time and selection. J Subst Abuse Treat 2018; 95:1–8.
15.
Stewart RE, Marcus SC, Hadley TR, et al: State adoption of incentives to promote evidence-based practices in behavioral health systems. Psychiatr Serv 2018; 69:685–688.
16.
Garnick DW, Horgan CM, Acevedo A, et al: Performance measures for substance use disorders—what research is needed? Addict Sci Clin Pract 2012; 7:18.

Information & Authors

Information

Published In

Go to Psychiatric Services
Go to Psychiatric Services
Psychiatric Services
Pages: 1219 - 1221
PubMed: 33853379

History

Received: 2 April 2020
Revision received: 11 November 2020
Accepted: 4 December 2020
Published online: 15 April 2021
Published in print: October 01, 2021

Keywords

  1. Financing
  2. Funding
  3. Reimbursement
  4. Community mental health centers
  5. Substance use treatment
  6. Behavioral health

Authors

Details

Rebecca E. Stewart, Ph.D.
Department of Psychiatry, Perelman School of Medicine and Leonard Davis Institute of Health Economics, University of Pennsylvania, Philadelphia (all authors); Penn Implementation Science Center at the Leonard Davis Institute of Health Economics, University of Pennsylvania, Philadelphia (Beidas).
David S. Mandell, Sc.D.
Department of Psychiatry, Perelman School of Medicine and Leonard Davis Institute of Health Economics, University of Pennsylvania, Philadelphia (all authors); Penn Implementation Science Center at the Leonard Davis Institute of Health Economics, University of Pennsylvania, Philadelphia (Beidas).
Rinad S. Beidas, Ph.D.
Department of Psychiatry, Perelman School of Medicine and Leonard Davis Institute of Health Economics, University of Pennsylvania, Philadelphia (all authors); Penn Implementation Science Center at the Leonard Davis Institute of Health Economics, University of Pennsylvania, Philadelphia (Beidas).

Notes

Send correspondence to Dr. Stewart ([email protected]).

Metrics & Citations

Metrics

Citations

Export Citations

If you have the appropriate software installed, you can download article citation data to the citation manager of your choice. Simply select your manager software from the list below and click Download.

For more information or tips please see 'Downloading to a citation manager' in the Help menu.

Format
Citation style
Style
Copy to clipboard

View Options

View options

PDF/EPUB

View PDF/EPUB

Login options

Already a subscriber? Access your subscription through your login credentials or your institution for full access to this article.

Personal login Institutional Login Open Athens login

Not a subscriber?

Subscribe Now / Learn More

PsychiatryOnline subscription options offer access to the DSM-5-TR® library, books, journals, CME, and patient resources. This all-in-one virtual library provides psychiatrists and mental health professionals with key resources for diagnosis, treatment, research, and professional development.

Need more help? PsychiatryOnline Customer Service may be reached by emailing [email protected] or by calling 800-368-5777 (in the U.S.) or 703-907-7322 (outside the U.S.).

Media

Figures

Other

Tables

Share

Share

Share article link

Share